Relieves symptoms associated with oral inflammatory lesions and ulcerative lesions…. ANDA 214582, held by Quagen. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 214582 (Triamcinolone Acetonide), held by Quagen, was first approved by FDA on Dec 9, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Triamcinolone Acetonide Dental Paste USP, 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 9, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.1% · paste;dental | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
